Remimazolam in obesity: lean weight to induce, adjusted weight to maintain

Design

Prospective population pharmacokinetic study with arterial sampling and external model validation

Population

44 adult volunteers across obesity classes; 30 (68.2%) with obstructive sleep apnoea

Primary outcome

Remimazolam and CNS7054 pharmacokinetic parameters and covariate effects

Effect

Clearance 1.09 L/min (RSE 4%); total body weight the only significant covariate; context-sensitive half-time 4.02 min after 4 h infusion in class 2/3 obesity

Remimazolam is marketed on a profile that suits patients living with obesity — organ-independent metabolism by tissue esterases, a short context-sensitive half-time — but which weight to dose it against has been guesswork, and the guess matters most in exactly the patients where it has been least studied.

Forty-four adult volunteers, 30 of them (68.2%) with obstructive sleep apnoea, received stepwise escalating infusions to a modified observer's assessment of alertness and sedation score of 1, with arterial sampling and a joint population model of remimazolam and its inactive metabolite CNS7054. Clearance was high, 1.09 L/min with a relative standard error of 4%. Total body weight significantly affected clearance and metabolite volume of distribution; no other covariate did, including obstructive sleep apnoea severity. In class 2 and 3 obesity the context-sensitive half-time after a four-hour infusion was 4.02 minutes.

The usable conclusion is a dosing rule with a model behind it: in class 2 and 3 obesity, dose on lean or ideal body weight for induction and adjusted body weight for maintenance, and the resulting concentration profile matches what total body weight dosing produces in a normal-weight patient. Dosing induction on total body weight in a patient of 140 kg will overshoot.

One caution, and the authors make it themselves. Obstructive sleep apnoea does not alter how the body handles the drug — it says nothing about how the airway responds to it. A short half-time is a property of the plasma, not a guarantee about the pharynx, and the monitoring and airway plan for a patient with severe sleep apnoea should not soften because the drug clears quickly.

• Induce on lean or ideal body weight in class 2 and 3 obesity; maintain on adjusted body weight.
• Do not use total body weight for the induction dose in severe obesity.
• Keep the sleep apnoea airway and monitoring plan unchanged — the pharmacokinetics say nothing about airway response.
• Calculate and write down the weight scalar you used, so the next dose is not guessed from the first.
• Expect fast offset after prolonged infusion — plan recovery monitoring for the airway, not for residual drug.

Why it matters

It replaces a guess about which weight to use with a modelled answer, in the patients where guessing is most dangerous.

Don't overread it

Pharmacokinetics in volunteers are not airway safety — this does not license lighter monitoring in sleep apnoea.

The statistics, in plain English

A relative standard error of 4% on clearance means the model estimates that parameter tightly — this is a well-identified model, not a fit stretched over sparse data. The important negative is that obstructive sleep apnoea severity was not a significant covariate: in a population pharmacokinetic model, that means apnoea severity added nothing to the prediction once body weight was accounted for, so any extra caution in these patients must be justified on pharmacodynamic grounds rather than on drug handling. With 44 volunteers, a small covariate effect could still have been missed.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.